{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-014543","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.411629+00:00","generated_at":"2026-05-27T02:45:15.782248+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Prelude Therapeutics appoints Bryant D. Lim as permanent CFO; base salary $483K","bullets":["Bryant D. Lim, previously interim CFO, appointed permanent CFO effective Feb 3, 2025; retains roles of Chief Legal Officer and Corporate Secretary.","Amended employment agreement provides base salary of $483,000, discretionary bonus up to 40% of base, and option for 200,000 shares vesting over 4 years.","Severance: nine months of base salary for termination without cause (non-change-of-control); twelve months for termination without cause or good reason related to change of control.","Option grant vests 25% on first anniversary and 1/48 monthly thereafter, subject to continued service."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-014543","json":"https://secwatch.observer/filing/0000950170-25-014543.json","markdown":"https://secwatch.observer/filing/0000950170-25-014543.md","text":"https://secwatch.observer/filing/0000950170-25-014543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025014543/0000950170-25-014543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025014543/prld-20250203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:45:15.782248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47adf990b0","claim":"Bryant D. Lim was appointed as Chief Financial Officer at Prelude Therapeutics Inc.","evidence_excerpt":"On February 3, 2025 (the “Effective Date”), the Board approved the appointment of Mr. Lim as the Company’s permanent Chief Financial Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025014543/0000950170-25-014543-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}